Galapagos NV

Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings

Retrieved on: 
Thursday, March 28, 2024
Warrant, EGM, Annual report, PDF, AGM, Euronext, Galapagos NV

Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm (CET) and 3:00 pm (CET), respectively, at the registered office of the Company.

Key Points: 
  • Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm (CET) and 3:00 pm (CET), respectively, at the registered office of the Company.
  • The annual report for the financial year 2023, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF.
  • Our annual 2023 Form 20-F filing with the SEC is available at www.sec.gov/edgar .
  • The convening notice and other documents pertaining to the Annual and Extraordinary Shareholders’ Meetings can be consulted on our website at www.glpg.com/shareholders-meetings .

Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

Retrieved on: 
Tuesday, March 26, 2024
CFO, Lazard, Patient, Sutter Health, Euronext, Galapagos NV, Management

Andrew Dickinson is Gilead's Chief Financial Officer (CFO) and replaces Daniel O’Day, Gilead’s Chairman and Chief Executive Officer (CEO), who was a member of the Galapagos Board of Directors from 22 October 2019 to 26 March 2024.

Key Points: 
  • Andrew Dickinson is Gilead's Chief Financial Officer (CFO) and replaces Daniel O’Day, Gilead’s Chairman and Chief Executive Officer (CEO), who was a member of the Galapagos Board of Directors from 22 October 2019 to 26 March 2024.
  • Mr. Dickinson is also a member of the Board of Directors of Sutter Health.
  • “On behalf of the Galapagos Board of Directors, I am very pleased to welcome Andy to our Board,” said Dr. Paul Stoffels1, CEO and Chairman of Galapagos.
  • The Board and I also want to sincerely thank Dan for his valuable contributions to the Galapagos Board of Directors.”
    “I am honored to step into Dan’s role as a member of the Galapagos Board of Directors,” said Mr. Dickinson.

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

Retrieved on: 
Thursday, February 22, 2024
NSCLC, NCT, Galapagos NV, Euronext, Safety, Pharmacokinetics, Medicine, Patient, Acceleration, Proteome, Clinical trial, Science, Medication, Pharmaceutical industry

BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced the close of an oversubscribed $80 million Series C financing. The financing was co-led by Deerfield Management Company and Droia Ventures, with significant participation from Galapagos NV (Euronext & NASDAQ: GLPG) as a strategic investor, and contributions from new and existing investors including DCVC Bio, MPM Capital, and RA Capital Management. This Series C financing brings the total capital raised since Frontier’s founding to $235.5 million.

Key Points: 
  • This Series C financing brings the total capital raised since Frontier’s founding to $235.5 million.
  • “Frontier Medicines is a leading chemoproteomics company with a unique technology platform and a pipeline of potential best-in-class assets that fit with Galapagos’ precision oncology R&D approach.
  • The participation in Frontier Medicines' Series C round aligns with our innovation acceleration strategy to bring transformational medicines to patients around the world.”
    Financing proceeds will support the advancement of multiple wholly-owned pipeline programs into clinical studies, including FMC-376.
  • “Today we mark the first participant dosed with a therapeutic candidate born from the Frontier™ Platform, alongside a financing that affirms continued strong investor support.

Galapagos presents at EBMT-EHA annual meeting 2024

Retrieved on: 
Thursday, February 15, 2024
Blood, Galapagos NV, European, Safety, Richter's transformation, CD19, Euronext, Multiple myeloma, EHA, DL2, EBMT, RT, Patient, Efficacy

Mechelen, Belgium; 15 February 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) to present new preliminary translational data and previously disclosed data at the European Society for Blood and Marrow Transplantation (EBMT)-European Hematology Association (EHA) 6th European CAR T-cell meeting taking place from 15–17 February 2024 in Valencia, Spain.

Key Points: 
  • Mechelen, Belgium; 15 February 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) to present new preliminary translational data and previously disclosed data at the European Society for Blood and Marrow Transplantation (EBMT)-European Hematology Association (EHA) 6th European CAR T-cell meeting taking place from 15–17 February 2024 in Valencia, Spain.
  • Further, previously disclosed safety, efficacy and feasibility data from EUPLAGIA-1 and ATALANTA-1 support the potential of Galapagos’ innovative approach to CAR-T manufacturing and of the transformational impact on patients with severe hematologic cancers.
  • “At Galapagos, we are committed to accelerating transformative innovation to address the unmet needs of patients with advanced cancers, and the data we are presenting today demonstrates our positive momentum toward this goal,” said Dr Jeevan Shetty, M.D., Head of Clinical Development Oncology at Galapagos.
  • Moreover, the abundance of both CD4+ and CD8+ TN/SCM CAR-T cells in the final product correlated with CAR-T-cell exposure in patients.

NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer

Retrieved on: 
Monday, February 5, 2024
Molecule, Euronext, Inflammation, Galapagos NV, CMO, Novartis, FMH, Maralixibat chloride, Patient, IPO, Disease, Neonatology, University, NLRP3, Pharmaceutical industry

NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer

Key Points: 
  • NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
    BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc., FMH as Chief Medical Officer (CMO), with effect from today.
  • With more than 20 years of experience across global large pharma, biotech and academic medicine, Dr. Jaecklin is an accomplished late-stage drug development leader.
  • Earlier in his career, Thomas served in key leadership roles in clinical and medical assessment, business development and market access at Novartis.
  • Alan Watt, Chief Executive Officer of NodThera, said: “We are delighted to welcome Thomas to the NodThera team, with his wealth of sector experience and successful execution of drug development programs across multiple therapeutic areas.

Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

Retrieved on: 
Wednesday, January 31, 2024
Euronext, Growth, Galapagos NV, Patient, Investment, Morgan Stanley, Acquisition

Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A.

Key Points: 
  • Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A.
    As previously announced, the transfer includes the entire Jyseleca® business, including the European and UK Marketing Authorizations, and the commercial, medical affairs and development activities for Jyseleca®.
  • In connection with the completion of the transaction, approximately 400 Galapagos positions in 14 European countries transferred to Alfasigma to support business continuity and ongoing patient access.
  • Michele Manto, former Chief Commercial Officer of Galapagos, also joins Alfasigma to lead the Jyseleca® business.
  • Galapagos will contribute up to €40 million to Alfasigma by June 2025 for Jyseleca® related development activities.

Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.

Retrieved on: 
Thursday, January 4, 2024
Technology transfer, Thermo Fisher Scientific, Research, TMO, Galapagos NV, Euronext, GMP, Patient, Pharmaceutical industry

Mechelen, Belgium; 4 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration agreement with Thermo Fisher Scientific, Inc. (NYSE: TMO) (“Thermo Fisher”) for the decentralized manufacturing of Galapagos’ point-of-care CAR-T product candidate in the San Francisco area.

Key Points: 
  • Mechelen, Belgium; 4 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration agreement with Thermo Fisher Scientific, Inc. (NYSE: TMO) (“Thermo Fisher”) for the decentralized manufacturing of Galapagos’ point-of-care CAR-T product candidate in the San Francisco area.
  • Under the terms of the agreement, Thermo Fisher will provide GMP manufacturing as well as BioServices and Specialty Logistics for Galapagos’ CAR-T hemato-oncology clinical program in the San Francisco area, effective January 2024.
  • Galapagos will initiate the technology transfer to enable Thermo Fisher’s manufacturing activities.
  • This collaboration follows Galapagos’ agreement with Landmark Bio for decentralized CAR-T manufacturing in the Boston area announced in November 2023.

BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets

Retrieved on: 
Wednesday, January 3, 2024
Galapagos NV, Euronext, Senior, Entrepreneurship, Cancer, Drug discovery, Partnering, SAN, Doctor of Philosophy, Pharmaceutical industry

SAN JOSE, Calif., Jan. 3, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditional "hard-to-drug" targets, announced today a strategic collaboration and licensing agreement with Galapagos NV (Euronext & NASDAQ: GLPG). Under the collaboration, BridGene will use its chemoproteomics platform, IMTAC™, to discover novel small molecule drug candidates against the collaboration targets. The parties will collaborate to advance the molecules to clinical candidates, which Galapagos has the exclusive rights to develop and commercialize.

Key Points: 
  • SAN JOSE, Calif., Jan. 3, 2024 /PRNewswire/ -- BridGene Biosciences, Inc. , a leader in the discovery of small molecule drugs for traditional "hard-to-drug" targets, announced today a strategic collaboration and licensing agreement with Galapagos NV (Euronext & NASDAQ: GLPG).
  • Under the collaboration, BridGene will use its chemoproteomics platform, IMTAC™, to discover novel small molecule drug candidates against the collaboration targets.
  • The preclinical research collaboration will focus on oncology targets named by Galapagos.
  • "We are excited to collaborate with Galapagos in the discovery of new drugs targeting critical and challenging targets in oncology.

Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Retrieved on: 
Wednesday, January 3, 2024
Galapagos NV, Euronext, Senior, Cancer, Patient, Drug discovery, Biotechnology, Pharmaceutical industry

Mechelen, Belgium; 3 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates.

Key Points: 
  • Mechelen, Belgium; 3 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates.
  • Through this collaboration, Galapagos and BridGene aim to discover and develop new precision medicines against clinically validated oncology targets by leveraging Galapagos’ expertise in small molecule drug discovery and translational research along with BridGene’s proprietary IMTAC™ chemoproteomics platform.
  • “We are very pleased to announce this preclinical research collaboration with BridGene, which has a strong track record in small molecule drug discovery for challenging targets.
  • In addition, BridGene will be entitled to receive single-digit tiered royalties on net sales of each product resulting from the collaboration.

Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

Retrieved on: 
Tuesday, January 2, 2024
Acquisition, Executive Committee, Galapagos NV, Euronext, Letter, Investment, Patient, Management

The agreement follows the signing of a letter of intent as announced on 30 October 2023.

Key Points: 
  • The agreement follows the signing of a letter of intent as announced on 30 October 2023.
  • “We would like to thank Michele for his contributions to Galapagos and are confident that his planned transition to Alfasigma will ensure business continuity through his close collaboration with the Jyseleca® team.
  • As previously announced, under the terms of the agreement, Alfasigma will acquire the entire Jyseleca® business, including the European and UK Marketing Authorizations, the commercial, medical affairs and development activities for Jyseleca® and approximately 400 Galapagos positions in 14 European countries.
  • Galapagos will contribute up to €40 million to Alfasigma by June 2025 for Jyseleca® related development activities.